JMKX003142-IV

JMKX003142-IV is an intravenous small molecule antagonist of the vasopressin V2 receptor (V2R), developed by Guangzhou Jiayue Pharmaceutical Technology (Jeyou Pharma). It is specifically designed for the treatment of cardiac edema, a condition characterized by fluid accumulation often associated with heart failure. By selectively blocking V2 receptors in the renal collecting ducts, the drug inhibits the water-reabsorbing effects of vasopressin, thereby promoting aquaresis—the excretion of electrolyte-free water. This mechanism helps to alleviate systemic fluid overload and reduce edema without the significant electrolyte imbalances often caused by traditional loop diuretics. While the parent compound JMKX003142 is also being investigated in oral formulations for autosomal dominant polycystic kidney disease (ADPKD) and renal edema, the JMKX003142-IV variant is optimized for intravenous administration in clinical settings requiring rapid or parenteral intervention for cardiac fluid retention.